AstraZeneca
AZN
466 hedge funds and large institutions have $12.3B invested in AstraZeneca in 2017 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 153 increasing their positions, 142 reducing their positions, and 42 closing their positions.
126% more call options, than puts
Call options by funds: $567M | Put options by funds: $251M
29% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 42
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
11% more capital invested
Capital invested by funds: $11.1B → $12.3B (+$1.21B)
1% more funds holding
Funds holding: 461 → 466 (+5)
8% more repeat investments, than reductions
Existing positions increased: 153 | Existing positions reduced: 142
0.19% more ownership
Funds ownership: 14.05% → 14.25% (+0.19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
+$299M |
| 2 |
Primecap Management
Pasadena,
California
|
+$117M |
| 3 |
Goldman Sachs
New York
|
+$40.9M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$22.9M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
+$21.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$110M |
| 2 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
-$96.2M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$63.6M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$57.8M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$51.5M |
AZN Hedge Fund Activity: Q2 2017 in Review
466 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2017, worth a combined $12.3B — up 11% from $11.1B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new AZN positions and 42 closed out — a net gain of 12 holders — while 153 added to existing stakes and 142 trimmed.
The largest buyer was Fisher Asset Management, adding an estimated $299M. The largest seller was Wellington Management Group, cutting an estimated $110M.
- 466 institutional investors held AstraZeneca (AZN) as of Q2 2017, up from 461 in Q1 2017.
- Funds reported $12.3B of AstraZeneca stock for Q2 2017, up 11% quarter-over-quarter.
- 54 funds opened new AstraZeneca positions in Q2 2017 and 42 closed out, a net change of +12 holders.
- The largest AstraZeneca buyer in Q2 2017 was Fisher Asset Management, an estimated $299M added.
- The largest AstraZeneca seller in Q2 2017 was Wellington Management Group, an estimated $110M sold.
Based on aggregated 13F filings for Q2 2017.